Literature DB >> 24757518

Novel HIV vaccine strategies: overview and perspective.

Yehuda Z Cohen1, Raphael Dolin2.   

Abstract

A human immunodeficiency virus (HIV) vaccine remains a central component in the quest to control the worldwide epidemic. To examine the status of the development of HIV vaccines, we review the results of the efficacy trials carried out to date and the immunologic principles that guided them. Four vaccine concepts have been evaluated in HIV-1 vaccine efficacy trials, and the results of these trials have provided significant information for future vaccine development. While one of these trials demonstrated that a safe and effective HIV vaccine is possible, many questions remain regarding the basis for the observed protection and the most efficient way to stimulate it. Novel HIV vaccine strategies including induction of highly potent broadly neutralizing antibodies, use of novel homologous and heterologous vector systems, and vectored immunoprophylaxis seek to expand and build upon the knowledge gained from these trials.

Entities:  

Keywords:  AIDSVAX; HIV vaccine; HIV vaccine clinical trials; HIV vaccine review; HVTN 505; RV144; Step

Year:  2013        PMID: 24757518      PMCID: PMC3967667          DOI: 10.1177/2051013613494535

Source DB:  PubMed          Journal:  Ther Adv Vaccines        ISSN: 2051-0136


  95 in total

1.  Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Authors:  Paul A Goepfert; Marnie L Elizaga; Alicia Sato; Li Qin; Massimo Cardinali; Christine M Hay; John Hural; Stephen C DeRosa; Olivier D DeFawe; Georgia D Tomaras; David C Montefiori; Yongxian Xu; Lilin Lai; Spyros A Kalams; Lindsey R Baden; Sharon E Frey; William A Blattner; Linda S Wyatt; Bernard Moss; Harriet L Robinson
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

2.  Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.

Authors:  Penny L Moore; Elin S Gray; Daniel Sheward; Maphuti Madiga; Nthabeleng Ranchobe; Zhong Lai; William J Honnen; Molati Nonyane; Nancy Tumba; Tandile Hermanus; Sengeziwe Sibeko; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Abraham Pinter; Lynn Morris
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

3.  Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.

Authors:  Miroslaw K Gorny; Leonidas Stamatatos; Barbara Volsky; Kathy Revesz; Constance Williams; Xiao-Hong Wang; Sandra Cohen; Robert Staudinger; Susan Zolla-Pazner
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 4.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.

Authors:  Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

5.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

6.  Common HIV-1 peptide variants mediate differential binding of KIR3DL1 to HLA-Bw4 molecules.

Authors:  Lena Fadda; Geraldine M O'Connor; Swati Kumar; Alicja Piechocka-Trocha; Clair M Gardiner; Mary Carrington; Daniel W McVicar; Marcus Altfeld
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

7.  The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.

Authors:  R Dolin; B S Graham; S B Greenberg; C O Tacket; R B Belshe; K Midthun; M L Clements; G J Gorse; B W Horgan; R L Atmar
Journal:  Ann Intern Med       Date:  1991-01-15       Impact factor: 25.391

8.  Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.

Authors:  Morgane Rolland; Sodsai Tovanabutra; Allan C deCamp; Nicole Frahm; Peter B Gilbert; Eric Sanders-Buell; Laura Heath; Craig A Magaret; Meera Bose; Andrea Bradfield; Annemarie O'Sullivan; Jacqueline Crossler; Teresa Jones; Marty Nau; Kim Wong; Hong Zhao; Dana N Raugi; Stephanie Sorensen; Julia N Stoddard; Brandon S Maust; Wenjie Deng; John Hural; Sheri Dubey; Nelson L Michael; John Shiver; Lawrence Corey; Fusheng Li; Steve G Self; Jerome Kim; Susan Buchbinder; Danilo R Casimiro; Michael N Robertson; Ann Duerr; M Juliana McElrath; Francine E McCutchan; James I Mullins
Journal:  Nat Med       Date:  2011-02-27       Impact factor: 53.440

9.  Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.

Authors:  David C Montefiori; Chitraporn Karnasuta; Ying Huang; Hasan Ahmed; Peter Gilbert; Mark S de Souza; Robert McLinden; Sodsai Tovanabutra; Agnes Laurence-Chenine; Eric Sanders-Buell; M Anthony Moody; Mattia Bonsignori; Christina Ochsenbauer; John Kappes; Haili Tang; Kelli Greene; Hongmei Gao; Celia C LaBranche; Charla Andrews; Victoria R Polonis; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Steve G Self; Phillip W Berman; Donald Francis; Faruk Sinangil; Carter Lee; Jim Tartaglia; Merlin L Robb; Barton F Haynes; Nelson L Michael; Jerome H Kim
Journal:  J Infect Dis       Date:  2012-05-25       Impact factor: 5.226

10.  Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.

Authors:  Morgane Rolland; Paul T Edlefsen; Brendan B Larsen; Sodsai Tovanabutra; Eric Sanders-Buell; Tomer Hertz; Allan C deCamp; Chris Carrico; Sergey Menis; Craig A Magaret; Hasan Ahmed; Michal Juraska; Lennie Chen; Philip Konopa; Snehal Nariya; Julia N Stoddard; Kim Wong; Hong Zhao; Wenjie Deng; Brandon S Maust; Meera Bose; Shana Howell; Adam Bates; Michelle Lazzaro; Annemarie O'Sullivan; Esther Lei; Andrea Bradfield; Grace Ibitamuno; Vatcharain Assawadarachai; Robert J O'Connell; Mark S deSouza; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Merlin L Robb; Jason S McLellan; Ivelin Georgiev; Peter D Kwong; Jonathan M Carlson; Nelson L Michael; William R Schief; Peter B Gilbert; James I Mullins; Jerome H Kim
Journal:  Nature       Date:  2012-09-10       Impact factor: 49.962

View more
  14 in total

1.  Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.

Authors:  Stephen R Walsh; Zoe Moodie; Andrew J Fiore-Gartland; Cecilia Morgan; Marissa B Wilck; Scott M Hammer; Susan P Buchbinder; Spyros A Kalams; Paul A Goepfert; Mark J Mulligan; Michael C Keefer; Lindsey R Baden; Edith M Swann; Shannon Grant; Hasan Ahmed; Fusheng Li; Tomer Hertz; Steven G Self; David Friedrich; Nicole Frahm; Hua-Xin Liao; David C Montefiori; Georgia D Tomaras; M Juliana McElrath; John Hural; Barney S Graham; Xia Jin
Journal:  J Infect Dis       Date:  2015-10-15       Impact factor: 5.226

2.  Identification of HIV-1-Based Virus-like Particles by Multifrequency Atomic Force Microscopy.

Authors:  Irene González-Domínguez; Sonia Gutiérrez-Granados; Laura Cervera; Francesc Gòdia; Neus Domingo
Journal:  Biophys J       Date:  2016-09-20       Impact factor: 4.033

3.  Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells.

Authors:  Jane C Yaciuk; Matthew Skaley; Wilfried Bardet; Fredda Schafer; Danijela Mojsilovic; Steven Cate; Christopher J Stewart; Curtis McMurtrey; Kenneth W Jackson; Rico Buchli; Alex Olvera; Samandhy Cedeño; Montserrat Plana; Beatriz Mothe; Christian Brander; John T West; William H Hildebrand
Journal:  J Virol       Date:  2014-08-27       Impact factor: 5.103

Review 4.  Human immunodeficiency virus vaccines.

Authors:  Paul Goepfert; Anju Bansal
Journal:  Infect Dis Clin North Am       Date:  2014-10-05       Impact factor: 5.982

5.  Synthetic biology approach for the development of conditionally replicating HIV-1 vaccine.

Authors:  Nanxi Wang; Zhe Yuan; Wei Niu; Qingsheng Li; Jiantao Guo
Journal:  J Chem Technol Biotechnol       Date:  2017-02-02       Impact factor: 3.174

Review 6.  Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines.

Authors:  Kyriakos A Hassapis; Dora C Stylianou; Leondios G Kostrikis
Journal:  Viruses       Date:  2014-12-17       Impact factor: 5.048

7.  M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures.

Authors:  Giuseppina Musumeci; Isabella Bon; David Lembo; Valeria Cagno; Maria Carla Re; Caterina Signoretto; Erica Diani; Lucia Lopalco; Claudia Pastori; Loïc Martin; Gilles Ponchel; Davide Gibellini; Kawthar Bouchemal
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

8.  Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.

Authors:  Amelia Escolano; Jon M Steichen; Pia Dosenovic; Daniel W Kulp; Jovana Golijanin; Devin Sok; Natalia T Freund; Alexander D Gitlin; Thiago Oliveira; Tatsuya Araki; Sarina Lowe; Spencer T Chen; Jennifer Heinemann; Kai-Hui Yao; Erik Georgeson; Karen L Saye-Francisco; Anna Gazumyan; Yumiko Adachi; Michael Kubitz; Dennis R Burton; William R Schief; Michel C Nussenzweig
Journal:  Cell       Date:  2016-09-08       Impact factor: 41.582

9.  Fcgbp - A Potential Viral Trap in RV144.

Authors:  Jacquelyn L Schwartz
Journal:  Open AIDS J       Date:  2014-09-08

Review 10.  Prevention strategies for blood-borne viruses-in the Era of vaccines, direct acting antivirals and antiretroviral therapy.

Authors:  Stephanie Pfaender; Thomas von Hahn; Joerg Steinmann; Sandra Ciesek; Eike Steinmann
Journal:  Rev Med Virol       Date:  2016-05-17       Impact factor: 6.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.